Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer

Abstract

A novel gene 08P1D4 (also designated STEAP-1) and its encoded protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.

1 .- 32 . (canceled)  
     
     
         33 . A method of inhibiting growth of cancer cells that express a protein of  FIG. 2  (SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, or 35), the method comprising: 
 administering to the cells an effective amount of a substance that modulates the status of a protein of  FIG. 2  (SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, or 35).    
     
     
         34 . The method of  claim 52   wherein substance is an antibody or a fragment thereof that specifically binds to a polypeptide of  FIG. 2  (SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, or 35).    
     
     
         35 . The method of  claim 33   wherein said substance is a STEAP-1-related protein.    
     
     
         36 . The method of  claim 33   wherein said substance is a polynucleotide comprising a coding sequence for a STEAP-1-related protein or comprising a polynucleotide complementary to a coding sequence for a STEAP-1-related protein.    
     
     
         37 . The method of  claim 33   wherein said substance is a ribozyme that cleaves a polynucleotide that encodes a protein of  FIG. 2  (SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, or 35).    
     
     
         38 . The method of  claim 33  wherein said cancer cells express a protein of  FIG. 2  and a particular HLA molecule, and the method comprises 
 administering human T cells to said cancer cells, wherein said T cells specifically recognize a peptide subsequence of a protein of  FIG. 2  while the subsequence is n to context of the particular HLA molecule.    
     
     
         39 . A method of  claim 33 , the method comprising steps of: 
 administering a vector that delivers a nucleotide that encodes a single chain monoclonal antibody, whereby the encoded single chain monoclonal antibody is expressed intracellularly within cancer cells that express a protein of  FIG. 2  (SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, or 35).    
     
     
         40 .- 51 . (canceled)  
     
     
         52 . The method of  claim 33  wherein said substance comprises an antibody or an antibody fragment that specifically binds to a protein of  FIG. 2  (SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, or 35).  
     
     
         53 . The method of  claim 34  wherein said substance is a monoclonal antibody or a fragment thereof.  
     
     
         54 . The method of  claim 53  wherein said substance is a human antibody, a humanized antibody or a chimeric antibody, of a fragment thereof.  
     
     
         55 . The method of  claim 53  wherein said cancer is selected from the group consisting of prostate cancer, gastric cancer colorectal cancer; multiple myeloma, B-cell lymphoma, leukemia, breast cancer, kidney cancer, bladder cancer, and lung cancer.  
     
     
         56 . The method of  claim 55  wherein said cancer is metastatic.  
     
     
         57 . The method of  claim 56  wherein said cancer is metastatic prostate cancer.  
     
     
         58 . The method of  claim 34  wherein the growth of said cancer cells is inhibited in a human patient.  
     
     
         59 . The method of  claim 58  wherein said human patient has been diagnosed with prostate cancer.  
     
     
         60 . The method of  claim 59  wherein said prostate cancer is advanced or metastatic prostate cancer.  
     
     
         61 . The method of  claim 59  wherein said human patient has received one or more rounds of chemotherapy prior to the administration of said antibody or antibody fragment.  
     
     
         62 . The method of  claim 58  wherein said antibody or antibody fragment is administered in conjunction with radiation, chemotherapy or hormone ablation.  
     
     
         63 . The method of  claim 58  wherein said antibody or antibody fragment is conjugated to a toxin, a radioisotope, or a chemotherapeutic agent.  
     
     
         64 . The method of  claim 63  wherein said chemotherapeutic agent is a maytansinoid.  
     
     
         65 . The method of  claim 58  wherein said human patient is diagnosed with breast cancer.  
     
     
         66 . The method of  claim 65  wherein said antibody or antibody fragment is co-administered with another cancer therapeutic agent.  
     
     
         67 . The method of  claim 66  wherein the other cancer therapeutic agent is trastuzumab or paclitaxel.